Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Medtronic
Colorcon
Harvard Business School
McKinsey

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR PIPERACILLIN SODIUM


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Piperacillin Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003805 ↗ Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 3 1997-11-01 RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count. It is not yet known which regimen of antibiotics is most effective in preventing infection in these patients. PURPOSE: Randomized phase III trial to study the effectiveness of piperacillin-tazobactam with or without vancomycin in reducing fever in patients who have leukemia, lymphoma, or Hodgkin's disease.
NCT00389987 ↗ Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037) Completed Merck Sharp & Dohme Corp. Phase 3 2001-09-01 This study is designed to compare the efficacy of ertapenem and piperacillin/tazobactam with respect to the clinical response in baseline microbiologically evaluable patients; and to evaluate the tolerability and safety of ertapenem compared to piperacillin/tazobactam.
NCT00873327 ↗ Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates Completed Phillip Brian Smith Phase 1 2009-10-01 This is a phase I open label multi-dose study to investigate the pharmacokinetics and safety of piperacillin-tazobactam in infants < 61 days of age with suspected sepsis. There will be four cohorts of 8 infants each: 1. < 32 weeks gestational age (GA) and < 14 days postnatal age (PNA) 2. < 32 weeks gestational age and >=14 days postnatal age 3. >=32 weeks gestational age and < 14 days postnatal age 4. >=32 weeks gestational age and >=14 days postnatal age. The study requires administration of 6 doses of study drug along with other antimicrobials per standard of care followed by 1 week of safety monitoring. Four 200 ┬ÁL pK samples will be obtained at steady state. The risks are reasonable vs. the benefits and have been minimized appropriately. There may be benefit to the subjects (administration of broad spectrum empirical antimicrobial therapy), and information from the study may benefit a large number of other infants in whom the drug is currently being administered despite the lack of PK data in this population.
NCT01370616 ↗ Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061) Completed Merck Sharp & Dohme Corp. Phase 3 2011-09-02 This study compared ertapenem sodium to piperacillin/tazobactam sodium for the treatment of moderate to severe diabetic foot infections. The primary hypothesis was that treatment with ertapenem sodium is non-inferior to treatment with piperacillin/tazobactam sodium, in achieving clinical improvement or cure.
NCT01760109 ↗ Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection Completed Xiangbei Welman Pharmaceutical Co., Ltd Phase 4 2011-07-01 In the proposed study, the investigators plan to evaluate the efficacy and safety of Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for the treatment of respiratory and urinary tract acute bacterial infection.
NCT01805856 ↗ Antimicrobial Prophylaxis in Thyroid and Parathyroid Surgery Completed Ito Hospital N/A 2010-11-01 The effectiveness of antimicrobial prophylaxis (AMP) for prevention of surgical site infection (SSI) following thyroid and parathyroid surgery remains uncertain. Present prospective randomized control study (Ito-RCT1) assessed the effectiveness of AMP in clean neck surgery associated with thyroid and parathyroid disease.
NCT01897831 ↗ Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection Unknown status Xiangbei Welman Pharmaceutical Co., Ltd Phase 4 2011-08-01 In the proposed study, the investigators plan to evaluate the efficacy and safety of Piperacillin sodium and sulbactam sodium for injection (2:1) for the treatment of respiratory and urinary tract acute bacterial infection under the widely used in clinical conditions.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Piperacillin Sodium

Condition Name

Condition Name for Piperacillin Sodium
Intervention Trials
Respiratory Tract Infections 2
Infection 2
Urinary Tract Infections 2
Atrial Fibrillation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Piperacillin Sodium
Intervention Trials
Infections 5
Infection 5
Communicable Diseases 5
Urinary Tract Infections 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Piperacillin Sodium

Trials by Country

Trials by Country for Piperacillin Sodium
Location Trials
United States 7
Canada 2
China 2
Turkey 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Piperacillin Sodium
Location Trials
Texas 1
North Carolina 1
Missouri 1
Kansas 1
Indiana 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Piperacillin Sodium

Clinical Trial Phase

Clinical Trial Phase for Piperacillin Sodium
Clinical Trial Phase Trials
Phase 4 3
Phase 3 3
Phase 2 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Piperacillin Sodium
Clinical Trial Phase Trials
Completed 7
Unknown status 3
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Piperacillin Sodium

Sponsor Name

Sponsor Name for Piperacillin Sodium
Sponsor Trials
Xiangbei Welman Pharmaceutical Co., Ltd 2
Merck Sharp & Dohme Corp. 2
Phillip Brian Smith 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Piperacillin Sodium
Sponsor Trials
Other 9
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Moodys
Baxter
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.